High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Open accessThe DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Abstract
CRISPR-Cas9 nucleases are widely used for genome editing but can induce unwanted off-target mutations. Existing strategies for reducing genome-wide off-target effects of the widely used Streptococcus pyogenes Cas9 (SpCas9) are imperfect, possessing only partial or unproven efficacies and other limitations that constrain their use. Here we describe SpCas9-HF1, a high-fidelity variant harbouring alterations designed to reduce non-specific DNA contacts. SpCas9-HF1 retains on-target activities comparable to wild-type SpCas9 with >85% of single-guide RNAs (sgRNAs) tested in human cells. Notably, with sgRNAs targeted to standard non-repetitive sequences, SpCas9-HF1 rendered all or nearly all off-target events undetectable by genome-wide break capture and targeted sequencing methods. Even for atypical, repetitive target sites, the vast majority of off-target mutations induced by wild-type SpCas9 were not detected with SpCas9-HF1. With its exceptional precision, SpCas9-HF1 provides an alternative to wild-type SpCas9 for research and therapeutic applications. More broadly, our results suggest a general strategy for optimizing genome-wide specificities of other CRISPR-RNA-guided nucleases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Precision editing of alleles in a human cell has drastically improved the understanding of genotypic and phenotypic effects in gene therapy due to the lower off-target rates [119,120,121].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To address off-target issues, using the CRISPR system in the form of a rRNP and utilizing high-fidelity CRISPR variants can help minimize off-target effects (Kleinstiver et al., 2016).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Kleinstiver et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Kleinstiver et al. developed the high-fidelity SpCas9-HF1, a variant that produced undetectable genome-wide off-target cleavage [134].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [134]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, a series of optimized mutations in SpCas9 have greatly improved the editing specificity of Cas9 variants without substantially attenuating the editing activity.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“Some active gRNAs for SpCas9-WT showed very low editing ability in SpCas9 variants.”
From Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing (2024) · cites this paper as [19]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearse, M., Moir, R., Wilson, A., Stones-Havas, S., Cheung, M., Sturrock, S., Buxton, S., Cooper, A., Markowitz, S., Duran, C., et al. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts199 · Cited by 20,027
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Self-citation
Cited by
Items 801–900 of 1,017
CRISPR based therapeutics: a new paradigm in cancer precision medicine
Das, S., Bano, S., Kapse, P., & Kundu, G. C. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01552-6 · Cited by 50
“SpCas9-high fidelity 1 (HF1) and “enhanced specificity” SpCas9 are two variants with lesser off-target activity [113, 114].”
BackgroundPrecise Genome Editing in Poultry and Its Application to Industries
Park, J. S., Lee, K. Y., & Han, J. Y. (2020) · Genes · doi:10.3390/genes11101182 · Cited by 49
“In addition, variants such as spCas9-HF1 and eSpCas9 were developed by protein engineering to improve the targeting specificity of Cas9 [26,27].”
BackgroundCRISPR-based strategies for targeted transgene knock-in and gene correction
Lau, C., Tin, C., & Suh, Y. (2020) · Faculty Reviews · doi:10.12703/r/9-20 · Cited by 51
Next-generation CRISPR-based diagnostic tools for human diseases
Wang, T., Wang, Z., Bai, L., Zhang, X., Feng, J., Qian, C., Wang, Y., & Wang, R. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117328 · Cited by 50
Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review
Long, C., Amoasii, L., Bassel‐Duby, R., & Olson, E. N. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3388 · Cited by 49
Abu-Bonsrah, K. D., Zhang, D., & Newgreen, D. F. (2016) · Scientific Reports · doi:10.1038/srep34524 · Cited by 55
Microbial CRISPRi and CRISPRa Systems for Metabolic Engineering
Zheng, Y., Su, T., & Qi, Q. (2019) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-019-0107-5 · Cited by 46
Current trends in Nanotechnology applications in surgical specialties and orthopedic surgery
Mariappan, N. M. (2019) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/1739 · Cited by 52
Induced Methylation in Plants as a Crop Improvement Tool: Progress and Perspectives
Mercé, C., Bayer, P. E., Fernandez, C. G. T., Batley, J., & Edwards, D. (2020) · Agronomy · doi:10.3390/agronomy10101484 · Cited by 49
Matsumoto, D., Tamamura, H., & Nomura, W. (2020) · Communications Biology · doi:10.1038/s42003-020-01340-2 · Cited by 49
FrCas9 is a CRISPR/Cas9 system with high editing efficiency and fidelity
Cui, Z., Tian, R., Huang, Z., Jin, Z., Li, L., Liu, J., Huang, Z., Xie, H., Liu, D., Mo, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29089-8 · Cited by 46
“The off-targets in GRIN2B-T9 site were as below: FrCas9 (0), SpCas9 (8), SpCas9-HF1 (6), HiFi-Cas9 (12) and eSpCas9 (7) (Fig.”
Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity
Huang, H., Huang, G., Tan, Z., Hu, Y., Shan, L., Zhou, J., Zhang, X., Ma, S., Lv, W., Huang, T., et al. (2022) · BMC Biology · doi:10.1186/s12915-022-01296-1 · Cited by 52
“In particular, protein engineering is an efficient and widely used approach for the development of high-fidelity Cas-nuclease variants, which has been well-proved in SpCas9, such as the unbiased engineered variants HiFi-Cas9 [17], evoCas9 [18], xCas9 [19], Sniper-Cas9 [20], LZ3-Cas9 [21], etc., and the structure-guide…”
BackgroundMethodInfluentialKulcsár, P. I., Tálas, A., Ligeti, Z., Krausz, S. L., & Welker, E. (2022) · Nature Communications · doi:10.1038/s41467-022-34527-8 · Cited by 43
Kulcsár, P. I., Tálas, A., Tóth, E., Nyeste, A., Ligeti, Z., Welker, Z., & Welker, E. (2020) · Nature Communications · doi:10.1038/s41467-020-15021-5 · Cited by 45
Structure of the human heparan sulfate polymerase complex EXT1-EXT2
Leisico, F., Omeiri, J., Le Narvor, C., Beaudouin, J., Hons, M., Fenel, D., Schoehn, G., Couté, Y., Bonnaffé, D., Sadir, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34882-6 · Cited by 45
CRISPR in Animals and Animal Models
Shrock, E., & Güell, M. (2017) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2017.07.010 · Cited by 45
Sattar, M. N., Iqbal, Z., Al-Khayri, J. M., & Jain, S. M. (2021) · Plants · doi:10.3390/plants10071347 · Cited by 49
Cheng, Y., Wang, H., & Li, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108524 · Cited by 50
Recent applications, future perspectives, and limitations of the CRISPR-Cas system
Park, S.-J., Lee, G. E., Cho, S. M., & Choi, E.-H. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102634 · Cited by 48
Application of CRISPR/Cas9 to Autophagy Research
O’Prey, J., Sakamaki, J.-I., Baudot, A. D., New, M., Acker, T. V., Tooze, S. A., Long, J. S., & Ryan, K. M. (2016) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2016.09.076 · Cited by 48
Krapivinsky, G. B., Krapivinsky, L., Renthal, N. E., Santa‐Cruz, A., Manasian, Y., & Clapham, D. E. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708427114 · Cited by 49
Okafor, I. C., Singh, D., Wang, Y., Jung, M., Wang, H., Mallon, J. P., Bailey, S., Lee, J. K., & Ha, T. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1058 · Cited by 53
Genome Editing for Mucopolysaccharidoses
Poletto, É., Baldo, G., & Gomez‐Ospina, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020500 · Cited by 50
Systematic in vitro profiling of off-target affinity, cleavage and efficiency for CRISPR enzymes
Zhang, L., Rube, H. T., Vakulskas, C. A., Behlke, M. A., Bussemaker, H. J., & Pufall, M. A. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa231 · Cited by 46
Helfricht, A., Thijssen, P. E., Rother, M. B., Shah, R. G., Du, L., Takada, S., Rogier, M., Moritz, J., IJspeert, H., Stoepker, C., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191688 · Cited by 46
“…cells were transfected by electroporation using the Neon transfection System (Thermo Fisher Scientific) with a plasmid expressing a gRNA targeting the first exon of m Zbtb24 (5 9 -AAG CTGCCCACAAGGCTCCG-3 9 ) and coexpressing the high-fidelity Cas9 nuclease (Kleinstiver et al., 2016) fused to EGFP.”
Hoffmann, M. D., Mathony, J., Upmeier zu Belzen, J., Harteveld, Z., Aschenbrenner, S., Stengl, C., Grimm, D., Correia, B. E., Eils, R., & Niopek, D. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1198 · Cited by 45
Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing
Domm, J. M., Wootton, S. K., Medin, J. A., & West, M. L. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.07.006 · Cited by 49
Battling CRISPR-Cas9 off-target genome editing
Li, D., Zhou, H., & Zeng, X. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09485-5 · Cited by 47
Structure of the human heparan sulfate polymerase complex EXT1-EXT2
(2022) · doi:10.1101/2022.06.19.496623 · Cited by 45
Optimization of Cas9 activity through the addition of cytosine extensions to single-guide RNAs
Kawamata, M., Suzuki, H. I., Kimura, R., & Suzuki, A. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01011-7 · Cited by 46
Engineered prime editors with minimal genomic errors
Chauhan, V. P., Sharp, P. A., & Langer, R. (2025) · Nature · doi:10.1038/s41586-025-09537-3 · Cited by 49
“Similar reductions in Cas9 activity were associated with efforts to improve on-target specificity, expand targeting space and alter repair outcomes 21,23–27 .”
Stem cell-based therapies for HIV/AIDS
Pernet, O., Yadav, S. S., & An, D. S. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.027 · Cited by 50
Genome editing and the next generation of antiviral therapy
Stone, D., Niyonzima, N., & Jerome, K. R. (2016) · Human Genetics · doi:10.1007/s00439-016-1686-2 · Cited by 46
“Therefore, diligence will be required to ensure that gene-editing therapies will be affordable for populations in developing nations who are disproportionally affected by chronic and persistent infections.”
BackgroundCRISPR/Cas9- loxP -Mediated Gene Editing as a Novel Site-Specific Genetic Manipulation Tool
Yang, F., Liu, C., Chen, D., Tu, M., Xie, H., Sun, H., Ge, X., Tang, L., Li, J., Zheng, J., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.018 · Cited by 50
Personalised genome editing – The future for corneal dystrophies
Moore, T., Christie, K. A., Marshall, J., & Nesbit, M. A. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.01.004 · Cited by 45
“proposed that the Cas9-sgRNA complex had more binding energy than it needed to carry out cleavage at on-target sites (Kleinstiver et al., 2016).”
BackgroundAnti‐CRISPRs: The natural inhibitors for CRISPR‐Cas systems
Zhang, F., Song, G., & Tian, Y. (2019) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12069 · Cited by 48
Thean, D., Chu, H. Y., Fong, J. H. C., Chan, B. K. C., Zhou, P., Kwok, C. C. S., Chan, Y. M., Mak, S. Y. L., Choi, G. C. G., Ho, J. W. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29874-5 · Cited by 48
“Experimental fitness (1) High-throughput experimental data collection”
Self-citationBodai, Z., Bishop, A. L., Gantz, V. M., & Komor, A. C. (2022) · Nature Communications · doi:10.1038/s41467-022-29989-9 · Cited by 50
Minimizing off-target effects in CRISPR-Cas9 genome editing
Chen, S. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09486-4 · Cited by 47
Paving the way towards precise and safe CRISPR genome editing
Śledziński, P., Dabrowska, M., Nowaczyk, M., & Olejniczak, M. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107737 · Cited by 45
Niu, R., Peng, J., Zhang, Z., & Shang, X. (2021) · Genes · doi:10.3390/genes12121878 · Cited by 48
“These off-target activities can confound research experiments and also affect the practical application of the technique [8].”
BackgroundLiu, S.-C., Feng, Y.-L., Sun, X., Chen, R.-D., Liu, Q., Xiao, J., Zhang, J., Huang, Z., Xiang, J.-F., Chen, G., et al. (2022) · Genome biology · doi:10.1186/s13059-022-02736-5 · Cited by 49
“7, and d SpCas9 were constructed previously [38, 39, 70].”
BackgroundAltered DNA repair pathway engagement by engineered CRISPR-Cas9 nucleases
Chauhan, V. P., Sharp, P. A., & Langer, R. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300605120 · Cited by 48
Zhou, J., Luan, X., Liu, Y., Wang, L., Wang, J., Yang, S., Liu, S., Zhang, J., Liu, H., & Yao, D. (2023) · Plants · doi:10.3390/plants12071478 · Cited by 51
Berman, A., Su, N., Li, Z., Landau, U., Chakraborty, J., Gerbi, N., Liu, J., Qin, Y., Yuan, B., Wei, W., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59280-6 · Cited by 44
CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses
Yuan, M., Webb, E., Lemoine, N. R., & Wang, Y. (2016) · Viruses · doi:10.3390/v8030072 · Cited by 48
Liu, Z., Hui, Y., Shi, L., Chen, Z., Xu, X., Chi, L., Fan, B., Fang, Y., Liu, Y., Ma, L., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.07.021 · Cited by 46
“Both NHEJ and HDR have been used in hPSCs for gene editing (Byrne et al., 2015; Chen et al., 2014b; Ding et al., 2013a; Ding et al., 2013b; Genga et al., 2015; Hockemeyer et al., 2011; Hou et al., 2013; Kleinstiver et al., 2016; Slaymaker et al., 2016).”
MethodCRISPR/Cas9: at the cutting edge of hepatology
Pankowicz, F. P., Jarrett, K. E., Lagor, W. R., & Bissig, K. (2017) · Gut · doi:10.1136/gutjnl-2016-313565 · Cited by 47
The Power of Zebrafish in Personalised Medicine
Baxendale, S., van Eeden, F. J. M., & Wilkinson, R. N. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-60733-7_10 · Cited by 52
Fusion guide RNAs for orthogonal gene manipulation with Cas9 and Cpf1
Kweon, J., Jang, A.-H., Kim, D., Yang, J. W., Yoon, M.-J., Shin, H. R., Kim, J., & Kim, Y. (2017) · Nature Communications · doi:10.1038/s41467-017-01650-w · Cited by 46
New tools for old drugs: Functional genetic screens to optimize current chemotherapy
Gerhards, N. M., & Rottenberg, S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.001 · Cited by 47
Hoes, M. F., Bömer, N., & van der Meer, P. (2018) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0052 · Cited by 48
CRISPR RNA-guided autonomous delivery of Cas9
Wilkinson, R. A., Martin, C. D., Nemudryi, A. A., & Wiedenheft, B. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0173-y · Cited by 48
Allele-specific genome targeting in the development of precision medicine
Wu, J., Tang, B., & Tang, Y. (2020) · Theranostics · doi:10.7150/thno.43298 · Cited by 46
Advances in genome editing for genetic hearing loss
Ding, N., Lee, S., Lieber-Kotz, M., Yang, J., & Gao, X. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.001 · Cited by 45
Novel genetic therapeutic approaches for modulating the severity of β‑thalassemia (Review)
Amjad, F., Fatima, T., Fayyaz, T., Khan, M. J., & Qadeer, M. I. (2020) · Biomedical Reports · doi:10.3892/br.2020.1355 · Cited by 49
Programmable Biosensors Based on RNA-Guided CRISPR/Cas Endonuclease
Liu, X., Hussain, M., Dai, J., Li, Y., Zhang, L., Yang, J., Ali, Z., He, N., & Tang, Y. (2022) · Biological Procedures Online · doi:10.1186/s12575-021-00163-7 · Cited by 44
“Two derivatives, high-fidelity (SpCas9-HF1) and enhanced specificity [eSpCas9] Cas9, have been shown to exhibit precise genome editing in human cells with reduced off-target mutations using both genome-wide and targeted sequencing methods [29, 30].”
BackgroundCardiac Organoids: A 3D Technology for Modeling Heart Development and Disease
Zhu, L., Liu, K. Y., Feng, Q., & Liao, Y. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10385-1 · Cited by 44
Prime editing primarily induces undesired outcomes in mice
Aida, T., Wilde, J. J., Yang, L., Hou, Y., Li, M., Xu, D., Lin, J., Qi, P., Lu, Z., & Feng, G. (2020) · doi:10.1101/2020.08.06.239723 · Cited by 43
“In particular, engineered enzymes have given the gene editing field an ever-expanding set of tools with increased fidelity (Kleinstiver et al., 2016; Slaymaker et al., 2016), altered target specificities (Chatterjee et al., 2018; Hu et al., 2018; Nishimasu et al., 2018; Walton et al., 2020), the…”
BackgroundMassively targeted evaluation of therapeutic CRISPR off-targets in cells
Pan, X., Qu, K., Yuan, H., Xiang, X., Anthon, C., Pashkova, L., Liang, X., Han, P., Corsi, G. I., Xu, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31543-6 · Cited by 42
Rational design of a compact CRISPR-Cas9 activator for AAV-mediated delivery
Vora, S., Cheng, J., Xiao, R., VanDusen, N. J., Quintino, L., Pu, W. T., Vandenberghe, L. H., Chavez, A., & Church, G. (2018) · doi:10.1101/298620 · Cited by 42
Szocik, K., Campa, R., Rappaport, M. B., & Corbally, C. J. (2019) · Space Policy · doi:10.1016/j.spacepol.2019.02.001 · Cited by 50
VERMA, K. K., Song, X., Yadav, G., Degu, H. D., Parvaiz, A., Singh, M., Huang, H.-R., Mustafa, G., Xu, L., & Li, Y. (2022) · ACS Omega · doi:10.1021/acsomega.2c01395 · Cited by 43
CRISPR/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics
Tiwari, P. K., Ko, T.-H., Dubey, R., Chouhan, M., Tsai, L.-W., Singh, H. N., Chaubey, K. K., Dayal, D., Chiang, C., & Kumar, S. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1214489 · Cited by 47
Burger, B. T., Beaton, B. P., Campbell, M. A., Brett, B. T., Rohrer, M. S., Plummer, S., Barnes, D., Jiang, K., Naswa, S., Lange, J., et al. (2024) · The CRISPR Journal · doi:10.1089/crispr.2023.0061 · Cited by 52
Factors affecting the cleavage efficiency of the CRISPR-Cas9 system
Jung, W. J., Park, S.-J., Cha, S., & Kim, K. (2024) · Animal Cells and Systems · doi:10.1080/19768354.2024.2322054 · Cited by 45
“Many researchers have attempted to optimize this tool by engineering Cas9 and sgRNA to overcome their limitations while increasing the editing efficiency (Kleinstiver et al. 2015; Kleinstiver et al. 2016; Park et al. 2021; Dong et al. 2022; Riesenberg et al. 2022).”
Backgroundvan Dongen, J. E., & Segerink, L. I. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00816 · Cited by 42
Alariqi, M., Ramadan, M., Yu, L., Hui, F., Hussain, A., Zhou, X., Yu, Y., Zhang, X., & Jin, S. (2025) · Advanced Science · doi:10.1002/advs.202416331 · Cited by 52
Ren, Q., Chen, L., Ma, Y., Huang, Y., & Wang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1563635 · Cited by 50
Collateral damage and CRISPR genome editing
Thomas, M., Burgio, G., Adams, D. J., & Iyer, V. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1007994 · Cited by 38
Therapeutic genome editing in cardiovascular diseases
Nishiga, M., Qi, L. S., & Wu, J. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.02.003 · Cited by 44
Wide Horizons of CRISPR-Cas-Derived Technologies for Basic Biology, Agriculture, and Medicine
Molla, K. A., Karmakar, S., & Islam, T. (2020) · Springer protocols handbooks/Springer protocols · doi:10.1007/978-1-0716-0616-2_1 · Cited by 61
Ullah, M., Xia, L., Xie, S., & Sun, S. (2020) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2077 · Cited by 44
Feng, Y.-L., Liu, S., Chen, R.-D., & Xie, A. (2021) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2000282 · Cited by 44
Review of applications of CRISPR-Cas9 gene-editing technology in cancer research
Zhao, Z., Li, C., Tong, F., Deng, J., Huang, G., & Sang, Y. (2021) · Biological Procedures Online · doi:10.1186/s12575-021-00151-x · Cited by 47
Cui, Y., Zhao, J. H., Gao, Y., Zhao, R., Zhang, J., & Kong, L. (2021) · Frontiers in Plant Science · doi:10.3389/fpls.2021.751891 · Cited by 44
“, 2016), SpCas9-HF1 (Kleinstiver et al., 2016), SpCas9-NGv1 (Endo et al.”
Li, J., Yu, X., Zhang, C., Li, N., & Zhao, J. (2022) · aBIOTECH · doi:10.1007/s42994-022-00076-3 · Cited by 44
“For example, based on structureguided protein engineering, eSpCas9(1.1) (Slaymaker et al. 2016) and SpCas9-HF1 (Kleinstiver et al. 2016) have been developed to reduce off-target effects.”
BackgroundInfluentialBhattacharyya, N., Anand, U., Kumar, R. S., Ghorai, M., Aftab, T., Jha, N. K., Rajapaksha, A. U., Bundschuh, J., Bontempi, E., & Dey, A. (2022) · Environmental Chemistry Letters · doi:10.1007/s10311-022-01474-1 · Cited by 46
Rittiner, J. E., Cumaran, M., Malhotra, S., & Kantor, B. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1035543 · Cited by 45
Applications and Prospects of CRISPR/Cas9-Mediated Base Editing in Plant Breeding
Li, Y., Liang, J. Y., Deng, B., Jiang, Y., Zhu, J., Chen, L., Li, M., & Li, J. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45020059 · Cited by 48
GUIDEseq: a bioconductor package to analyze GUIDE-Seq datasets for CRISPR-Cas nucleases
Zhu, L. J., Lawrence, M., Gupta, A., Pagès, H., Kucukural, A., Garber, M., & Wolfe, S. A. (2017) · BMC Genomics · doi:10.1186/s12864-017-3746-y · Cited by 40
Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing
Zhang, Y., Long, C., Bassel‐Duby, R., & Olson, E. N. (2018) · Physiological Reviews · doi:10.1152/physrev.00046.2017 · Cited by 45
“The high-fidelity SpCas9 (SpCas9-HF1) was generated by alanine substitution to disrupt nonspecific interaction with the target DNA strand (191).”
BackgroundLi, X., Wang, C., Peng, T., Chai, Z., Ni, D., Liu, Y., Zhang, J., Chen, T., & Lu, S. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.11.010 · Cited by 44
Goel, K., & Ploski, J. E. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.914430 · Cited by 42
Negative DNA supercoiling induces genome-wide Cas9 off-target activity
Newton, M. D., Losito, M., Smith, Q. M., Parnandi, N., Taylor, B., Akçakaya, P., Maresca, M., van Eijk, P., Reed, S. H., Boulton, S. J., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.09.008 · Cited by 45
Satapathy, B. P., Sheoran, P., Yadav, R., Chettri, D., Sonowal, D., Dash, C. P., Dhaka, P., Uttam, V., Yadav, R., Jain, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1389971 · Cited by 43
Unlocking Fungal Potential: The CRISPR-Cas System as a Strategy for Secondary Metabolite Discovery
Leal, K., Rojas, E., Madariaga-Troncoso, D., Contreras, M. J., Núñez-Montero, K., Barrientos, L., Gómez-Espinoza, O., & Iturrieta‐González, I. (2024) · Journal of Fungi · doi:10.3390/jof10110748 · Cited by 45
Advances in CRISPR/Cas9-Based Gene Editing in Filamentous Fungi
Ma, B., Li, Y., Wang, T., Li, D., & Jia, S. (2025) · Journal of Fungi · doi:10.3390/jof11050350 · Cited by 41
Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus
Ely, A., Moyo, B., & Arbuthnot, P. B. (2016) · Molecular Therapy · doi:10.1038/mt.2016.43 · Cited by 42
Sato, M., Ohtsuka, M., Watanabe, S., & Gurumurthy, C. B. (2016) · Biology Direct · doi:10.1186/s13062-016-0115-8 · Cited by 45
CRISPR-Mediated Epigenome Editing.
Enríquez, P. (2016) · PubMed Central · Cited by 62
Engineering Point Mutant and Epitope‐Tagged Alleles in Mice Using Cas9 RNA‐Guided Nuclease
Gertsenstein, M., & Nutter, L. M. J. (2018) · Current Protocols in Mouse Biology · doi:10.1002/cpmo.40 · Cited by 42
“Several groups have developed high-fidelity Cas9 (e.g., Kleinstiver et al., 2016; Slaymaker et al., 2016) tested in cell lines, and a proprietary version of highfidelity Cas9 is now commercially available (Integrated DNA Technologies, 1078727).”
BackgroundMariscal, A. M., Kakizawa, S., Hsu, J. Y., Tanaka, K., González‐González, L., Broto, A., Querol, E., Lluch‐Senar, M., Piñero‐Lambea, C., Sun, L., et al. (2018) · ACS Synthetic Biology · doi:10.1021/acssynbio.8b00028 · Cited by 45
Human Genomic Safe Harbors and the Suicide Gene-Based Safeguard System for iPSC-Based Cell Therapy
Kimura, Y., Shofuda, T., Higuchi, Y., Nagamori, I., Oda, M., Nakamori, M., Onodera, M., Kanematsu, D., Yamamoto, A., Katsuma, A., et al. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0039 · Cited by 55
RNA-guided piggyBac transposition in human cells
Hew, B. E., Sato, R., Mauro, D., Stoytchev, I., & Owens, J. B. (2019) · Synthetic Biology · doi:10.1093/synbio/ysz018 · Cited by 46
CRISPR/Cas Derivatives as Novel Gene Modulating Tools: Possibilities and In Vivo Applications
Xu, X., Hulshoff, M. S., Tan, X., Zeisberg, M., & Zeisberg, E. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093038 · Cited by 44
“These four amino acid substitutions alter the energetics of the binding of SpCas9 to the DNA, and thereby the specificity, which diminished off-target effects [14].”
BackgroundTargeted Gene Delivery: Where to Land
Pavani, G., & Amendola, M. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.609650 · Cited by 55
The Use of CRISPR/Cas9 as a Tool to Study Human Infectious Viruses
Lin, H., Li, G., Peng, X., Deng, A., Ye, L., Shi, L., Wang, T., & He, J. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.590989 · Cited by 50
Emerging therapeutic targets for cerebral edema
Jha, R. M., Raikwar, S. P., Mihaljević, S., Casabella, A. M., Catapano, J. S., Rani, A., Desai, S. M., Gerzanich, V., & Simard, J. M. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2010045 · Cited by 42
CRISPR–Cas9 gene editing induced complex on-target outcomes in human cells
Wen, W., & Zhang, X. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.03.002 · Cited by 42
Metadata
- Authors
- Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- City University of Hong Kong (HK)
- Corresponding author
- Joung, J. Keith
- ORCID
- Venue
- Nature
- Published
- 2016-01-06
- Volume
- 529
- Issue
- 7587
- Pages
- 490-495
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4851738
- OpenAlex
- W2224398381
- Cited by
- 2,673
- References
- 47
- Citations by year
- 2026: 189 · 2025: 221 · 2024: 200 · 2023: 181 · 2022: 267 · 2021: 273 · 2020: 287 · 2019: 284 · 2018: 284 · 2017: 267 · 2016: 215
- FWCI
- 181.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (DP1GM105378, R01GM107427, R01GM088040)
- National Center for Chronic Disease Prevention and Health Promotion (DP1 GM105378)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, off-target mutations, Streptococcus pyogenes, single guide RNA, targeted sequencing, genome editing
- MeSH terms
- Base Sequence, DNA, DNA-Binding Proteins, Endonucleases, Genetic Engineering, Humans, Mutation, Protein Binding, RNA, Streptococcus pyogenes, Substrate Specificity, Reproducibility of Results, Genome, Human, Sequence Analysis, DNA, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.